Stifel downgraded Mirati Therapeutics to Hold from Buy with a price target of $59, down from $83.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRTX:
- Mirati Therapeutics reports Q3 EPS ($2.49), consensus ($2.83)
- Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
- MRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Mirati Therapeutics receives MHRA approval for KRAZATI
- Kura Oncology, Mirati Therapeutics enter clinical collab, supply agreement